Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 113-120

  Kamen, B A ^a   Smith, A K ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anti folate; Farletuzumab; Folate receptor; Pemetrexed

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FARLETUZUMAB; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLIC ACID; PEMETREXED;

ARTICLE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG UPTAKE; GROWTH INHIBITION; IC 50; IN VITRO STUDY; MEMBRANE BINDING; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING, COMPETITIVE; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLATE RECEPTOR 1; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; KINETICS; TETRAHYDROFOLATES; TRITIUM;

EID: 84863483737     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1890-2     Document Type: Article

References (21)

1. Fox JT, Stover PJ (2008) Folate-mediated one-carbon metabolism. In: Litwack G (ed) Vitamins and hormones: folic acid and folates (vol 79). Elsevier, Philadelphia, pp 1-29
2. Kamen BA, Cole P, Bertino JR (2006) Chemotherapeutic agents: folic acid antagonists. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine. Williams and Wilkins, Philadelphia, pp 648-660
3. Westerhof GR, Schornagel JH, Kathmann I et al (1995) Carrierand receptor mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471
4. Elnakat H, Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067-1084 (Pubitemid 38496508)
5. Leamon CP, Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127-1141 (Pubitemid 38496512)
6. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288-5295
7. Spannuth WA, Sood AK, Coleman RL (2010) Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10:431-437
8. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27:2686-2691
9. Tomao F, Panici PB, Frati L, Tomao S, Federica et al (2009) Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 9:1727-1735
10. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:1-8
11. Chattopadhyay S, Wang Y, Zhao R, Goldman ID (2004) Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 10:7986-7993 (Pubitemid 39587540)
12. Nutt JE, Razak AR, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J (2010) The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 102:553-560
13. Kamen BA, Smith AK (2004) A review of folate receptor alpha cycling and 5-methyltetra-hydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 56:1085-1097 (Pubitemid 38496509)
14. Kamen BA, Capdevilla A (1986) Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 83:5983-5987 (Pubitemid 16000638)
15. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RGW (1988) Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 263:13602-13609
16. Kamen BA, Wang M-T, Johnson C, Anderson RGW (1989) Regulation of the cytoplasmic accumulation of 5-Methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. J Clin Invest 84:1379-1386 (Pubitemid 19272222)
17. Nichols B (2009) Endocytosis of lipid-anchored proteins: excluding GEECs from the crowd. J Cell Biol 186:457-459
18. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74:854-862
19. Zhao R, Matherly LH, Goldman ID (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4. doi:10.1017/S1462399409000969
20. Birn H, Spiegelstein O, Christensen EI, Finnell RH (2005) Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol 16:608-615 (Pubitemid 41725097)
21. Lewis CM, Smith AK, Nguyen C, Kamen BA (1998) PMA alters folate receptor distribution in the plasma membrane and increases the rate of 5-methyltetrahydrofolate delivery in mature MA104 cells. Biochim Biophys Acta 1401:157-169 (Pubitemid 28129098)